Critical Appraisal of Bevacizumab in the Treatment of Metastatic Colorectal Cancer

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s30581
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

PCN22 Safety Profile of Bevacizumab in Metastatic Colorectal Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation

OncoTargets and Therapy
OncologyPharmacology
2013English

Molecular Targeted Treatment of Metastatic Colorectal Cancer: The Cardiovascular Adverse Effects of Bevacizumab and Cetuximab

Medicine and Pharmacy Reports
Medicine
2017English

Effect and Safety of Bevacizumab-Containing Chemotherapy Treatment in Chinese Patients With Metastatic Colorectal Cancer

OncoTargets and Therapy
OncologyPharmacology
2013English

Systematic Review and Economic Evaluation of Bevacizumab and Cetuximab for the Treatment of Metastatic Colorectal Cancer

Health Technology Assessment
MedicineHealth Policy
2007English

Advances in the Treatment of Metastatic Colorectal Cancer

Disease-a-Month
Medicine
2010English

Reply: Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2010English

Modeling Efficacy of Bevacizumab Treatment for Metastatic Colon Cancer

Journal of Cancer
Oncology
2013English

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients

Frontiers in Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy